Advertisement

Diabetologia

, Volume 61, Issue 12, pp 2598–2607 | Cite as

Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging

  • Gary W. Cline
  • Mika Naganawa
  • Laigao Chen
  • Kristin Chidsey
  • Santos Carvajal-Gonzalez
  • Sylvester Pawlak
  • Michelle Rossulek
  • Yanwei Zhang
  • Jason Bini
  • Timothy J. McCarthy
  • Richard E. Carson
  • Roberto A. Calle
Article

Abstract

Aims/hypothesis

The progressive loss of beta cell function is part of the natural history of type 2 diabetes. Autopsy studies suggest that this is, in part, due to loss of beta cell mass (BCM), but this has not been confirmed in vivo. Non-invasive methods to quantify BCM may contribute to a better understanding of type 2 diabetes pathophysiology and the development of therapeutic strategies. In humans, the localisation of vesicular monoamine transporter type 2 (VMAT2) in beta cells and pancreatic polypeptide cells, with minimal expression in other exocrine or endocrine pancreatic cells, has led to its development as a measure of BCM. We used the VMAT2 tracer [18F]fluoropropyl-(+)-dihydrotetrabenazine to quantify BCM in humans with impaired glucose tolerance (prediabetes) or type 2 diabetes, and in healthy obese volunteers (HOV).

Methods

Dynamic positron emission tomography (PET) data were obtained for 4 h with metabolite-corrected arterial blood measurement in 16 HOV, five prediabetic and 17 type 2 diabetic participants. Eleven participants (six HOV and five with type 2 diabetes) underwent two abdominal PET/computed tomography (CT) scans for the assessment of test–retest variability. Standardised uptake value ratio (SUVR) was calculated in pancreatic subregions (head, body and tail), with the spleen as a reference region to determine non-specific tracer uptake at 3–4 h. The outcome measure SUVR minus 1 (SUVR-1) accounts for non-specific tracer uptake. Functional beta cell capacity was assessed by C-peptide release following standard (arginine stimulus test [AST]) and acute insulin response to the glucose-enhanced AST (AIRargMAX). Pearson correlation analysis was performed between the binding variables and the C-peptide AUC post-AST and post-AIRargMAX.

Results

Absolute test–retest variability (aTRV) was ≤15% for all regions. Variability and overlap of SUVR-1 was measured in all groups; HOV and participants with prediabetes and with type 2 diabetes. SUVR-1 showed significant positive correlations with AIRargMAX (all groups) in all pancreas subregions (whole pancreas p = 0.009 and pancreas head p = 0.009; body p = 0.019 and tail p = 0.023). SUVR-1 inversely correlated with HbA1c (all groups) in the whole pancreas (p = 0.033) and pancreas head (p = 0.008). SUVR-1 also inversely correlated with years since diagnosis of type 2 diabetes in the pancreas head (p = 0.049) and pancreas tail (p = 0.035).

Conclusions/interpretation

The observed correlations of VMAT2 density in the pancreas and pancreas regions with years since diagnosis of type 2 diabetes, glycaemic control and beta cell function suggest that loss of BCM contributes to deficient insulin secretion in humans with type 2 diabetes.

Keywords

Beta cell mass Pancreas PET imaging Type 2 diabetes VMAT2 

Abbreviations

AST

Arginine stimulus test

AIRarg

Acute insulin response to arginine for the standard AST

AIRargMAX

Acute insulin response to the glucose-enhanced AST

aTRV

Absolute test–retest variability

BCM

Beta cell mass

COV

Coefficient of variation

CT

Computed tomography

FBG

Fasting blood glucose

18F-FP-(+)-DTBZ

[18F]fluoropropyl-(+)-dihydrotetrabenazine

HOV

Healthy obese volunteer

MRI

Magnetic resonance imaging

PCRU

Pfizer Clinical Research Unit

PET

Positron emission tomography

PP-(cells)

Pancreatic polypeptide (cells)

ROI

Region of interest

SUV

Standardised uptake value

SUVR

Standardised uptake value ratio

TRV

Test–retest variability

VMAT2

Vesicular monoamine transporter type 2

Notes

Acknowledgements

The authors appreciate the excellent technical assistance of staff at the Yale University PET Center, especially PET Technologists D. Ruggiero and E. Hidalgo, and the New Haven PCRU.

Some of the data were presented as an abstract at the ADA 76th Scientific Sessions, 10–14 June 2016, New Orleans, LA, USA.

Contribution statement

All authors contributed to the conception and design of the study/protocol. LC, KC, SC-G, MR and JB researched data and contributed to discussion. GWC, MN and REC wrote the manuscript and researched data. All authors contributed to discussion and reviewed/edited the manuscript. All authors approved the final version of the manuscript. GWC is the guarantor of this work, had full access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis.

Funding

This work was supported by the Yale-Pfizer Bioimaging Research Alliance and National Institutes of Health (NIH) grant 1S10OD010322-01. This publication was also made possible by Clinical and Translational Science Award Grant Number UL1 TR000142 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH.

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript. The sponsor, Pfizer Worldwide R&D, was involved in study design and data collection and provided editorial assistance.

Supplementary material

125_2018_4624_MOESM1_ESM.pdf (170 kb)
ESM (PDF 170 kb)

References

  1. 1.
    Liu YQ, Jetton TL, Leahy JL (2002) Beta-cell adaptation to insulin resistance. Increased pyruvate carboxylase and malate-pyruvate shuttle activity in islets of nondiabetic Zucker fatty rats. J Biol Chem 277:39163–39168CrossRefGoogle Scholar
  2. 2.
    Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110CrossRefGoogle Scholar
  3. 3.
    Marselli L, Suleiman M, Masini M et al (2014) Are we overestimating the loss of beta cells in type 2 diabetes? Diabetologia 57:362–365CrossRefGoogle Scholar
  4. 4.
    Wang X, Misawa R, Zielinski MC et al (2013) Regional differences in islet distribution in the human pancreas—preferential beta-cell loss in the head region in patients with type 2 diabetes. PLoS One 8:e67454CrossRefGoogle Scholar
  5. 5.
    Goland R, Freeby M, Parsey R et al (2009) 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med 50:382–389CrossRefGoogle Scholar
  6. 6.
    Normandin MD, Petersen KF, Ding YS et al (2012) In vivo imaging of endogenous pancreatic beta-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET. J Nucl Med 53:908–916CrossRefGoogle Scholar
  7. 7.
    Carlbom L, Espes D, Lubberink M et al (2017) [11C]5-Hydroxy-tryptophan PET for assessment of islet mass during progression of type 2 diabetes. Diabetes 66:1286–1292CrossRefGoogle Scholar
  8. 8.
    Brom M, Woliner-van der Weg W, Joosten L et al (2014) Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin. Diabetologia 57:950–959CrossRefGoogle Scholar
  9. 9.
    Eriksson O, Espes D, Selvaraju RK et al (2014) Positron emission tomography ligand [11C]5-hydroxy-tryptophan can be used as a surrogate marker for the human endocrine pancreas. Diabetes 63:3428–3437CrossRefGoogle Scholar
  10. 10.
    Freeby MJ, Kringas P, Goland RS et al (2016) Cross-sectional and test-retest characterization of PET with [(18)F]FP-(+)-DTBZ for beta cell mass estimates in diabetes. Mol Imaging Biol 18:292–301CrossRefGoogle Scholar
  11. 11.
    Freeby M, Ichise M, Harris PE (2012) Vesicular monoamine transporter, type 2 (VMAT2) expression as it compares to insulin and pancreatic polypeptide in the head, body and tail of the human pancreas. Islets 4:393–397CrossRefGoogle Scholar
  12. 12.
    Harris PE, Ferrara C, Barba P, Polito T, Freeby M, Maffei A (2008) VMAT2 gene expression and function as it applies to imaging beta-cell mass. J Mol Med 86:5–16CrossRefGoogle Scholar
  13. 13.
    Saisho Y, Harris PE, Butler AE et al (2008) Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas. J Mol Histol 39:543–551CrossRefGoogle Scholar
  14. 14.
    Eriksson O, Laughlin M, Brom M et al (2016) In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and use. Diabetologia 59:1340–1349CrossRefGoogle Scholar
  15. 15.
    Fagerholm V, Mikkola KK, Ishizu T et al (2010) Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. J Nucl Med 51:1439–1446CrossRefGoogle Scholar
  16. 16.
    Singhal T, Ding YS, Weinzimmer D et al (2011) Pancreatic beta cell mass PET imaging and quantification with [11C]DTBZ and [18F]FP-(+)-DTBZ in rodent models of diabetes. Mol Imaging Biol 13:973–984CrossRefGoogle Scholar
  17. 17.
    Naganawa M, Lin SF, Lim K et al (2016) Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of 18F-FP-DTBZ in baboons. Nucl Med Biol 43:743–751CrossRefGoogle Scholar
  18. 18.
    Harris PE, Farwell MD, Ichise M (2013) PET quantification of pancreatic VMAT 2 binding using (+) and (-) enantiomers of [(1)(8)F]FP-DTBZ in baboons. Nucl Med Biol 40:60–64CrossRefGoogle Scholar
  19. 19.
    Robertson RP, Raymond RH, Lee DS et al (2014) Arginine is preferred to glucagon for stimulation testing of beta-cell function. Am J Phys Endocrinol Metab 307:E720–E727CrossRefGoogle Scholar
  20. 20.
    Shankar SS, Vella A, Raymond RH et al (2016) Standardized mixed-meal tolerance and arginine stimulation tests provide reproducible and complementary measures of beta-cell function: results from the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series. Diabetes Care 39:1602–1613CrossRefGoogle Scholar
  21. 21.
    Pavlidis T (1982) Algorithms for graphics and image processing. Computer Science Press, Berlin HeidelbergCrossRefGoogle Scholar
  22. 22.
    Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC (2008) Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 10(Suppl 4):32–42CrossRefGoogle Scholar
  23. 23.
    Saisho Y, Butler AE, Manesso E, Elashoff D, Rizza RA, Butler PC (2013) Beta-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care 36:111–117CrossRefGoogle Scholar
  24. 24.
    Kilbourn MR, Hockley B, Lee L et al (2007) Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain. Nucl Med Biol 34:233–237CrossRefGoogle Scholar
  25. 25.
    Kung MP, Hou C, Goswami R, Ponde DE, Kilbourn MR, Kung HF (2007) Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl Med Biol 34:239–246CrossRefGoogle Scholar
  26. 26.
    Rahier J, Wallon J, Loozen S, Lefevre A, Gepts W, Haot J (1983) The pancreatic polypeptide cells in the human pancreas: the effects of age and diabetes. J Clin Endocrinol Metab 56:441–444CrossRefGoogle Scholar
  27. 27.
    Wang X, Zielinski MC, Misawa R et al (2013) Quantitative analysis of pancreatic polypeptide cell distribution in the human pancreas. PLoS One 8:e55501CrossRefGoogle Scholar
  28. 28.
    Spijker HS, Song H, Ellenbroek JH et al (2015) Loss of beta-cell identity occurs in type 2 diabetes and is associated with islet amyloid deposits. Diabetes 64:2928–2938CrossRefGoogle Scholar
  29. 29.
    Wang YJ, Schug J, Won KJ et al (2016) Single-cell transcriptomics of the human endocrine pancreas. Diabetes 65:3028–3038CrossRefGoogle Scholar
  30. 30.
    Talchai C, Xuan S, Lin HV, Sussel L, Accili D (2012) Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell 150:1223–1234CrossRefGoogle Scholar
  31. 31.
    Sakano D, Shiraki N, Kikawa K et al (2014) VMAT2 identified as a regulator of late-stage beta-cell differentiation. Nat Chem Biol 10:141–148CrossRefGoogle Scholar
  32. 32.
    Jung SH, Jung CH, Reaven GM, Kim SH (2018) Adapting to insulin resistance in obesity: role of insulin secretion and clearance. Diabetologia 61:681–687CrossRefGoogle Scholar
  33. 33.
    Yoon KH, Ko SH, Cho JH et al (2003) Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 88:2300–2308CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Gary W. Cline
    • 1
  • Mika Naganawa
    • 1
  • Laigao Chen
    • 2
  • Kristin Chidsey
    • 2
  • Santos Carvajal-Gonzalez
    • 2
  • Sylvester Pawlak
    • 2
  • Michelle Rossulek
    • 2
  • Yanwei Zhang
    • 2
  • Jason Bini
    • 1
  • Timothy J. McCarthy
    • 2
  • Richard E. Carson
    • 1
  • Roberto A. Calle
    • 2
  1. 1.Yale UniversityNew HavenUSA
  2. 2.Pfizer Worldwide R&DCambridgeUSA

Personalised recommendations